Abstract Details

Title Serum Procalcitonin Level as a Predictor for Prognostic Outcomes in Traumatic Brain Injury Patients: A Systematic Review and Meta-analysis

Topic Neuro Trauma and Critical Care

Presentation(s) S26 - Neuro Trauma and Sports Neurology (2:24 PM-2:36 PM)

Poster/Presentation
Number 008

Background Predicting TBI patients’ clinical outcomes is challenging. PCT have gained attention for its prognostic potential in other conditions; however, its role in TBI is still unclear.

Objective We aim to assess the prognostic value of procalcitonin (PCT) in traumatic brain injury (TBI) patients.

Design/Methods We searched PubMed, Embase, Cochrane, Scopus, and Web of Science databases for studies measuring serum PCT levels post-TBI and addressing outcomes like sepsis, mortality, and infection. Quality assessment was conducted using the Newcastle-Ottawa Scale (NOS). We pooled PCT values as mean difference (MD) and 95% confidence intervals (CI). Heterogeneity was assessed using the I² test.

Results Our analysis included 11 observational studies with a total of 958 TBI patients. Serum PCT levels were significantly elevated on the first day of admission (0.983 ng/mL, 95% CI: 0.554–1.412), progressively decreasing over time, dropping to 0.498 (95% CI: 0.254–0.743) on day 2 and 0.358 (95% CI: 0.268–0.448) on day 3. Non-survivors had significantly higher PCT levels on day one of ICU admission (MD: 5.23 ng/mL, 95% CI: 1.26, 9.21; p=0.01). Patients who developed sepsis had significantly higher PCT levels on first day (MD: 0.21 ng/mL, 95% CI: 0.12, 0.30; p<0.0001), which remained elevated on days 2 and 5. Infected patients did not have a significantly higher PCT levels on the first day (MD: 0.05 ng/mL, 95% CI: –0.71, 0.81, p=0.68).

Conclusions Serum PCT levels may serve as a useful prognostic biomarker for mortality and sepsis in TBI patients, particularly during the early phase of intensive care. While PCT did not significantly predict infection, its robust association with mortality and sepsis supports its potential use in clinical decision-making for TBI patients.

Authors/Disclosures
Ahmed Negida, MD, PhD (Virginia Commonwealth University) PRESENTER	Dr. Negida has nothing to disclose.
Abdelrahman M. Tawfik, MD	Dr. Tawfik has nothing to disclose.
Abdalla M. Hadhoud, MD	Mr. Hadhoud has nothing to disclose.
Abdelrahman Elshimy, MBBS	Dr. Elshimy has nothing to disclose.
Abdullah Azzam, MBBS	Dr. Azzam has nothing to disclose.
Rawan A. Hassanien, MBBS	Dr. Hassanien has nothing to disclose.
Shrouk Ramadan, MD	Dr. Ramadan has nothing to disclose.

��ɫ��

��ɫ��